These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 34903548)

  • 1. Analysis of
    Pilling LC; Türkmen D; Fullalove H; Atkins JL; Delgado J; Kuo CL; Kuchel GA; Ferrucci L; Bowden J; Masoli JAH; Melzer D
    BMJ Open; 2021 Dec; 11(12):e053905. PubMed ID: 34903548
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of Genotype-Guided Oral P2Y12 Inhibitor Selection vs Conventional Clopidogrel Therapy on Ischemic Outcomes After Percutaneous Coronary Intervention: The TAILOR-PCI Randomized Clinical Trial.
    Pereira NL; Farkouh ME; So D; Lennon R; Geller N; Mathew V; Bell M; Bae JH; Jeong MH; Chavez I; Gordon P; Abbott JD; Cagin C; Baudhuin L; Fu YP; Goodman SG; Hasan A; Iturriaga E; Lerman A; Sidhu M; Tanguay JF; Wang L; Weinshilboum R; Welsh R; Rosenberg Y; Bailey K; Rihal C
    JAMA; 2020 Aug; 324(8):761-771. PubMed ID: 32840598
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased frequency of CYP2C19 loss-of-function alleles in clopidogrel-treated patients with recurrent cerebral ischemia.
    Minderhoud C; Otten LS; Hilkens PHE; van den Broek MPH; Harmsze AM
    Br J Clin Pharmacol; 2022 Jul; 88(7):3335-3340. PubMed ID: 35176816
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of CYP2C19 polymorphism in prognosis of minor stroke or TIA patients with declined eGFR on dual antiplatelet therapy: CHANCE substudy.
    Wu Y; Zhou Y; Pan Y; Zhao X; Liu L; Wang D; Wang C; Li H; Johnston SC; Meng X; Wang Y; Wang Y;
    Pharmacogenomics J; 2018 Dec; 18(6):713-720. PubMed ID: 29520080
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ticagrelor Aspirin vs Clopidogrel Aspirin in
    Wang A; Meng X; Tian X; Zuo Y; Bath PM; Li H; Xie X; Jing J; Lin J; Wang Y; Zhao X; Liu L; Li Z; Jiang Y; Xu J; Wang F; Chen W; Cao M; Li J; Wang Y
    Neurology; 2023 Jan; 100(5):e497-e504. PubMed ID: 36535779
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk of stroke in CYP2C19 LoF polymorphism carrier coronary artery disease patients undergoing clopidogrel therapy: An ethnicity-based updated meta-analysis.
    Jafrin S; Naznin NE; Reza MS; Aziz MA; Islam MS
    Eur J Intern Med; 2021 Aug; 90():49-65. PubMed ID: 34092486
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CYP2C19 loss-of-function alleles and use of omeprazole or esomeprazole increase the risk of cardiovascular outcomes in patients using clopidogrel.
    Ramste M; Ritvos M; Häyrynen S; Kiiski JI; Niemi M; Sinisalo J
    Clin Transl Sci; 2023 Oct; 16(10):2010-2020. PubMed ID: 37551775
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CYP2C19 and CES1 polymorphisms and efficacy of clopidogrel and aspirin dual antiplatelet therapy in patients with symptomatic intracranial atherosclerotic disease.
    Hoh BL; Gong Y; McDonough CW; Waters MF; Royster AJ; Sheehan TO; Burkley B; Langaee TY; Mocco J; Zuckerman SL; Mummareddy N; Stephens ML; Ingram C; Shaffer CM; Denny JC; Brilliant MH; Kitchner TE; Linneman JG; Roden DM; Johnson JA
    J Neurosurg; 2016 Jun; 124(6):1746-51. PubMed ID: 26587656
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical Outcomes and Sustainability of Using
    Lee CR; Sriramoju VB; Cervantes A; Howell LA; Varunok N; Madan S; Hamrick K; Polasek MJ; Lee JA; Clarke M; Cicci JD; Weck KE; Stouffer GA
    Circ Genom Precis Med; 2018 Apr; 11(4):e002069. PubMed ID: 29615454
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CYP2C19 polymorphisms and clopidogrel efficacy in the secondary prevention of ischemic stroke: a retrospective observational study.
    Lin J; Mo Y; Cai D; Mao D; Fu H; Wei D
    Ann Palliat Med; 2021 Dec; 10(12):12171-12180. PubMed ID: 35016407
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association Between CYP2C19 Loss-of-Function Allele Status and Efficacy of Clopidogrel for Risk Reduction Among Patients With Minor Stroke or Transient Ischemic Attack.
    Wang Y; Zhao X; Lin J; Li H; Johnston SC; Lin Y; Pan Y; Liu L; Wang D; Wang C; Meng X; Xu J; Wang Y;
    JAMA; 2016 Jul; 316(1):70-8. PubMed ID: 27348249
    [TBL] [Abstract][Full Text] [Related]  

  • 12.
    Beitelshees AL; Thomas CD; Empey PE; Stouffer GA; Angiolillo DJ; Franchi F; Tuteja S; Limdi NA; Lee JC; Duarte JD; Kreutz RP; Skaar TC; Coons JC; Giri J; McDonough CW; Rowland R; Stevenson JM; Thai T; Vesely MR; Wellen JT; Johnson JA; Winterstein AG; Cavallari LH; Lee CR;
    J Am Heart Assoc; 2022 Feb; 11(4):e024159. PubMed ID: 35156424
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of CYP2C19*2 and *3 loss-of-function alleles on platelet reactivity and adverse clinical events in East Asian acute myocardial infarction survivors treated with clopidogrel and aspirin.
    Jeong YH; Tantry US; Kim IS; Koh JS; Kwon TJ; Park Y; Hwang SJ; Bliden KP; Kwak CH; Hwang JY; Gurbel PA
    Circ Cardiovasc Interv; 2011 Dec; 4(6):585-94. PubMed ID: 22045970
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Variant recurrent risk among stroke patients with different CYP2C19 phenotypes and treated with clopidogrel.
    Sun W; Li Y; Li J; Zhang Z; Zhu W; Liu W; Cai Q; Wang X; Cao L; Bai W; Fan X; Ma M; Guo R; Liu X; Xu G
    Platelets; 2015; 26(6):558-62. PubMed ID: 25207801
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of CYP2C19 Loss-of-Function Metabolizer Status With Stroke Risk Among Chinese Patients Treated With Ticagrelor-Aspirin vs Clopidogrel-Aspirin: A Prespecified Secondary Analysis of a Randomized Clinical Trial.
    Xie X; Johnston SC; Wang A; Xu Q; Bath PM; Pan Y; Li H; Lin J; Wang Y; Zhao X; Li Z; Jiang Y; Liu L; Xu A; Jing J; Meng X; Wang Y
    JAMA Netw Open; 2023 Jun; 6(6):e2317037. PubMed ID: 37279000
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clopidogrel preventive effect based on cytochrome P450 2C19 genotype in ischaemic stroke: protocol for multicentre observational study.
    Song TJ; Kim J; Han SW; Kim YD; Lee JY; Ahn SH; Lee HS; Jung YH; Lee KY
    BMJ Open; 2020 Aug; 10(8):e038031. PubMed ID: 32759249
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patients carrying CYP2C19 loss of function alleles have a reduced response to clopidogrel therapy and a greater risk of in-stent restenosis after endovascular treatment of lower extremity peripheral arterial disease.
    Guo B; Tan Q; Guo D; Shi Z; Zhang C; Guo W
    J Vasc Surg; 2014 Oct; 60(4):993-1001. PubMed ID: 24877854
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of CYP2C19*2 and *3 on clinical outcome in ischemic stroke patients treated with clopidogrel.
    Wang Y; Cai H; Zhou G; Zhang Z; Liu X
    J Neurol Sci; 2016 Oct; 369():216-219. PubMed ID: 27653892
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Time Course for Benefit and Risk With Ticagrelor and Aspirin in Individuals With Acute Ischemic Stroke or Transient Ischemic Attack Who Carry CYP2C19 Loss-of-Function Alleles: A Secondary Analysis of the CHANCE-2 Randomized Clinical Trial.
    Pan Y; Meng X; Jin A; Johnston SC; Li H; Bath PM; Xie X; Jing J; Lin J; Wang Y; Zhao X; Li Z; Jiang Y; Liu L; Yang H; Cheng J; Wang Z; Wang Y
    JAMA Neurol; 2022 Aug; 79(8):739-745. PubMed ID: 35727586
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of clopidogrel high on-treatment reactivity with clinical outcomes and gene polymorphism in acute ischemic stroke patients: An observational study.
    Fu H; Hu P; Ma C; Peng F; He Z
    Medicine (Baltimore); 2020 Apr; 99(15):e19472. PubMed ID: 32282698
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.